Stock 688505 SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Shanghai S.E.

Equities

688505

CNE100004BN8

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-06-30 EDT 		5-day change 1st Jan Change
6.5 CNY +1.56% Intraday chart for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. -3.13% -29.58%
06-21 Fudan Zhangjiang Bio-Pharmaceutical Enrolls First Patient for Glioma Drug Trial MT
06-21 Shanghai Fudan Zhangjiang Bio-Pharmaceutical Terminates Libod Marketing Agreement MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Fudan Zhangjiang Bio-Pharmaceutical Enrolls First Patient for Glioma Drug Trial
MT
Shanghai Fudan Zhangjiang Bio-Pharmaceutical Terminates Libod Marketing Agreement
MT
Shanghai Fudan-Zhangjiang Terminates Marketing Agreement
MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces First Patient Enrolled in Confirmatory Clinical Trial of Aminolevulinic Acid Hydrochloride Powder for Oral Solution for Intraoperative Visualisation of Glioma
CI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023
MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023, Payable on August 26, 2024
CI
Fudan-Zhangjiang Bio's 2023 Profit Falls
MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application
CI
Chinese Regulator NMPA Grants Acceptance Notice for Shanghai Fudan-Zhangjiang's Investigational Drug
MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug
CI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Notification of Approval for Supplementary Drug Application
CI
Fudan-Zhangjiang's Profit Drops 70.5% in Q3
MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Fudan-Zhangjiang Bio Gets Nod for Cancer Drug Trial
MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC
CI
Fudan-Zhangjiang Bio Swings to Profit in H1
MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Announces First Patient Enrolled in Phase I Clinical Trial of FZ-AD004 Antibody Drug Conjugate for the Treatment of Advanced Solid Tumors
CI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1349 Stock
  4. 688505 Stock
  5. News Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
  6. Highlights